We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Yissum Introduces a Novel Technology for Drug Screening and Testing of Orphan Diseases
News

Yissum Introduces a Novel Technology for Drug Screening and Testing of Orphan Diseases

Yissum Introduces a Novel Technology for Drug Screening and Testing of Orphan Diseases
News

Yissum Introduces a Novel Technology for Drug Screening and Testing of Orphan Diseases

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Yissum Introduces a Novel Technology for Drug Screening and Testing of Orphan Diseases"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Animal models are commonly used to study novel molecules for various diseases, but this approach suffers from various limitations. For example, numerous developmental diseases cannot be studied using animal models, nor by isolating cells from patients.

Now Yissum has introduced a novel platform technology for screening and evaluating small molecules as potential drugs for various human genetic disorders, which are essentially orphan diseases. The method, developed by Prof. Nissim Benvenisty, Director, The Azrieli Center for Stem Cells and Genetic Research at the Hebrew University, utilizes human pluripotent stem cells (hPSCs) as a model system that overcomes several limitations inherent to animal models.

As part of the novel approach, Prof. Benvenisty's Center has generated hPSCs representing human genetic disorders, such as Fragile X syndrome or Down syndrome, as well as other genetic conditions such as some types of cancers or hereditary diabetes.

Prof. Benvenisty and his group have developed 15 disease cell models for 13 genetic disorders, which can serve not only to understand the molecular basis underlying these diseases, but also as platforms for screening small molecules to treat these disorders.

In addition, since the cellular models are derived from human cells, they can also serve to validate potential drugs intended for the treatment of human developmental genetic disorders.

Yaccov Michlin, CEO of Yissum, commented, “The new disease model system developed by Prof. Benvenisty offers a complementary approach that can address many of the hurdles inherent to animal models. We are certain that this novel method will have a significant impact on drug screening and development, and Yissum is currently looking for partners in order to further advance this promising approach.”

Animal models are an important step in the research and development of many drugs, but often fall short due to various limitations. This cellular system, based on human stem cells, enables, for example, cost-effective high throughput screening of small molecules as potential drugs for a variety of genetic and other conditions, screening which is not possible using many animal models.

Furthermore, the ability to manipulate the genome of these cells in order to emulate various genetic diseases offers an extensive potential to study, understand and develop new therapies for many complex diseases with an underlying genetic basis.

Advertisement